LICENSE AGREEMENTLicense Agreement • December 23rd, 2021 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This License Agreement is effective as of November 23, 2015 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC. (“Licensee”), a Delaware corporation located at 329 Oyster Point Blvd, South San Francisco, 94080.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 23rd, 2021 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment (“Amendment”) is entered into effective as of April 9, 2019 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 as amended on November 13, 2017 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI“), and BLACKTHORN THERAPEUTICS, NC., a Delaware corporation (“Licensee”).
LICENSE AGREEMENTLicense Agreement • December 23rd, 2021 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 15th day of June, 2020 (the “Effective Date”), by and between Syllable Life Sciences, Inc., a corporation existing under the laws of Delaware, having a place of business at c/o Cambridge Innovation Center, 1 Broadway, 14th floor, Cambridge, MA 02142 (“Syllable”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727E, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • December 23rd, 2021 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO LICENSE AGREEMENT (“Amendment No. 1”) is effective March 31, 2021 (the “Amendment No. 1 Effective Date”) and is made by and between Syllable Life Sciences, Inc. (“Syllable”), and the President and Fellows of Harvard College, (“Harvard”). This Amendment No. 1 shall serve as an amendment to that certain License Agreement dated June 15, 2020 by and between the parties (the “Agreement”). Except as expressly modified hereby, the Agreement shall continue in full force according to its terms. Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the same meaning as set forth in the Agreement.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 23rd, 2021 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (“Amendment”) is entered into effective as of November 13, 2017 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 (the “License Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC., a Delaware corporation (“Licensee”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement.
